Technical analyst Anil Singhvi has maintained 'buy' rating on Orchid Chemicals & Pharmaceuticals Limited stock with an intra-day target of Rs 295.

According to analyst, the investors can buy the stock with stop loss of Rs 277.

The stock of the company, on December 22, closed at Rs 281.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 344.40 and a low of Rs 128 on BSE.

Current EPS is -72.43.

Orchid Chemicals & Pharmaceuticals Ltd, an India-based company, which makes APIs, and makes and sells formulations in Indian and export market.

Orchid Chemicals & Pharmaceuticals Ltd has a multi-therapeutic attendance across sections such as anti-inflammatory, anti-infectives, inhibitors, central nervous system, cardio vascular zone, functional foods, and other oral and sterile products.

The company has two API complexes, 3 formulation making plants and 2 r&d centers and one API making plant in China.

The different divisions of the company consisted Orchid Research Lab Ltd, India, Bexel Pharmaceutical Inc., USA, Orchid Europe Limited, UK and Orchid Pharmaceutical Inc., USA.